Current guidelines (ADA-2023, KIDGO-2022, and ESC-2023) recommend SGLT-2 inhibitors and GLP-1 receptor agonists as first-line therapies in type 2 diabetes patients with cardiovascular disease, chronic kidney disease, and heart failure. Here, SLC5A2 is linked to chronic kidney disease.